Evogene (EVGN) Stock Price, News & Analysis

Company Overview

Evogene Ltd. is an Israel-based computational biology company that develops products and technologies for the life sciences and agriculture industries. Founded in 1999 and headquartered in Rehovot, Israel, the company uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and machine-learning tools to identify and develop novel biological products.

Evogene’s activities have included agricultural solutions such as crop-protection products, bio-stimulants and microbiome-based technologies. The company has pursued these opportunities through subsidiaries and business units including Lavie Bio, which focuses on microbiome-based agricultural products, and AgPlenus, which develops computationally designed crop-protection solutions. Its programs are intended to support applications such as improved crop performance, disease control and more sustainable agricultural production.

Evogene has also explored human-health applications through businesses such as Canonic, which focused on the development of medical cannabis products, and other microbiome-related research initiatives. The company’s technology and development programs are aimed at serving global agricultural and life-science markets through partnerships, product development and commercialization activities.

Key Stats

• Today's Range: $0.37 to $0.39
• 50-Day Range: $0.38 to $0.70
• 52-Week Range: $0.35 to $1.49
• Volume: 105,888 shs
• Average Volume: 3.82 million shs
• Market Capitalization: $3.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Evogene Stock Analysis - MarketRank™

Evogene scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Evogene has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Evogene has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evogene are expected to grow in the coming year, from ($1.10) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evogene is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evogene is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evogene has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.55% of the float of Evogene has been sold short.

Short Interest Ratio / Days to Cover

Evogene has a short interest ratio ("days to cover") of 0.15, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evogene has recently increased by 1,541.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evogene does not currently pay a dividend.

Dividend Growth

Evogene does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.20

News Sentiment

Evogene has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Evogene this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $294,400.00 in company stock, which represents 8.8335% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Evogene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $294,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of Evogene is held by insiders.

Percentage Held by Institutions

10.40% of the stock of Evogene is held by institutions.

Company Calendar

• Last Earnings: 5/16/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EVGN
• CIK: 1574565
• Web: www.evogene.com
• Phone: (728) 931-1900
• Fax: 972-8946-6724
• Employees: 52
• Year Founded: 1999

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.48 million
• Net Margins: -694.18%
• Pretax Margin: -1,230.53%
• Return on Equity: -156.53%
• Return on Assets: -86.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.57
• Quick Ratio: 3.54

Sales & Book Value

• Annual Sales: $3.85 million
• Price / Sales: 0.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 8,720,000
• Free Float: 8,073,000
• Market Cap: $3.33 million
• Optionable: No Data
• Beta: 1.44